Brief: Theravance Biopharma- On Dec 26 Units, Mylan Ireland & Mylan Specialty L.P. Entered Settlement Agreement With Accord Healthcare
28/12/2023 11:18
Dec 28 (Reuters) - Theravance Biopharma Inc TBPH.O :
* ON DEC 26 UNITS, MYLAN IRELAND & MYLAN SPECIALTY L.P.
ENTERED
SETTLEMENT AGREEMENT WITH ACCORD HEALTHCARE
* SETTLEMENT AGREEMENT WITH ACCORD HEALTHCARE RELATING TO
THERAVANCE AND MYLAN'S YUPELRI (REVEFENACIN) INHALATION SOLUTION
* UNDER DEAL, ACCORD GRANTED LICENSE TO MANUFACTURE, MARKET
ACCORD'S GENERIC VERSION OF YUPELRI IN U.S ON/ AFTER APRIL 23,
2039
Source text for Eikon: ID:
Further company coverage: TBPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theravance Biopharma
See all newsIreland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth
Ireland's Theravance Biopharma Q4 revenue misses expectations
Corrected: BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million
U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group
U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy